Therapies: Elan’s commitment to advancing science and changing lives
Alzheimer’s Disease Therapy
On August 6, 2012 Johnson & Johnson announced the discontinuation of Phase 3 development of bapineuzumab IV in mild to moderate Alzheimer's based on the co-primary clinical endpoints not being met. A subcutaneous formulation of bapineuzumab is in Phase 2 testing. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development.
Multiple Sclerosis Therapy
As announced on April 2, 2013, Elan completed the disposal of its Tysabri IP and rights to Biogen Idec. As a result, Elan received an upfront payment of $3.25 bn and continuing double digit tiered royalties on Tysabri in-market sales. Tysabri is marketed and distributed solely by Biogen Idec.